We are live on ! Find out more
GBIO

Generation Bio
GBIO

Delisted

GBIO was delisted on the 6th of February, 2026.

Back to rankings

2 hedge funds and large institutions have $53.3K invested in Generation Bio in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% less ownership

Funds ownership: 64% → 0% (-64%)

96% less funds holding

Funds holding: 48 → 2 (-46)

100% less capital invested

Capital invested by funds: $24.5M → $53.3K (-$24.5M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 45

Holders
2
Holders Change
-46
Holders Change %
-95.83%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
45
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
Accent Capital Management
Ohio
+$195

Top Sellers

Rank Fund Capital Flow
1
AVLSA
Atlas Venture Life Science Advisors
Massachusetts
-$4.7M
2
SCP
SymBiosis Capital Partners
Arkansas
-$3.78M
3
OM
Opaleye Management
Massachusetts
-$1.76M
4
Renaissance Technologies
Renaissance Technologies
New York
-$1.63M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$1.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
Accent Capital Management
Ohio
$53.3K +$195 +35 +135%
AVLSA
2
Atlas Venture Life Science Advisors
Massachusetts
– -$4.7M -827,946 Closed
SCP
3
SymBiosis Capital Partners
Arkansas
– -$3.78M -665,000 Closed
OM
4
Opaleye Management
Massachusetts
– -$1.76M -310,000 Closed
Renaissance Technologies
5
Renaissance Technologies
New York
– -$1.63M -287,614 Closed
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
– -$1.19M -209,641 Closed
SL
7
Siren LLC
Connecticut
– -$1.14M -201,419 Closed
UBS Group
8
UBS Group
Switzerland
– -$936K -164,716 Closed
Morgan Stanley
9
Morgan Stanley
New York
– -$917K -161,378 Closed
Marshall Wace
10
Marshall Wace
United Kingdom
– -$797K -140,294 Closed
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
– -$686K -121,029 Closed
YCM
12
Yiheng Capital Management
California
– -$599K -105,524 Closed
RC
13
Rangeley Capital
Connecticut
– -$558K -98,280 Closed
Goldman Sachs
14
Goldman Sachs
New York
– -$520K -91,527 Closed
Millennium Management
15
Millennium Management
New York
– -$503K -88,563 Closed
Bank of America
16
Bank of America
North Carolina
– -$482K -84,842 Closed
BlackRock
17
BlackRock
New York
– -$341K -60,070 Closed
Geode Capital Management
18
Geode Capital Management
Massachusetts
– -$294K -51,795 Closed
Two Sigma Investments
19
Two Sigma Investments
New York
– -$287K -50,557 Closed
Citadel Advisors
20
Citadel Advisors
Florida
– -$268K -47,245 Closed
DS
21
DRW Securities
Illinois
– -$249K -43,812 Closed
DAM
22
Deltec Asset Management
New York
– -$185K -32,650 Closed
TD Asset Management
23
TD Asset Management
Ontario, Canada
– -$152K -26,708 Closed
LCM
24
Lynx1 Capital Management
Puerto Rico
– -$142K -25,000 Closed
TC
25
Torno Capital
Massachusetts
– -$142K -25,000 Closed
1
2

GBIO Hedge Fund Activity: Q1 2026 in Review

2 of the 8,158 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q1 2026, worth a combined $53.3K — down 100% from $24.5M a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of GBIO and 0 opened new positions — a net loss of 45 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Accent Capital Management, adding an estimated $195. The largest seller was Atlas Venture Life Science Advisors, exiting entirely with an estimated $4.7M sold.

  • 2 institutional investors held Generation Bio (GBIO) as of Q1 2026, down from 48 in Q4 2025.
  • Funds reported $53.3K of Generation Bio stock for Q1 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Generation Bio positions in Q1 2026 and 45 closed out, a net change of -45 holders.
  • The largest Generation Bio buyer in Q1 2026 was Accent Capital Management, an estimated $195 added.
  • The largest Generation Bio seller in Q1 2026 was Atlas Venture Life Science Advisors, an estimated $4.7M sold.

Based on aggregated 13F filings for Q1 2026.